The treatment of psoriatic patients with biolocs has greatly changed the progression of the disease , the clinical outcomes and the quality of life of the patients. The problem of these innovative treatment are the cost. We report a real life experience with adalimumab biosimilar which proved to be affective and safe with a low cost profile.
Clinical experience with infliximab biosimilar in psoriasis / Ricceri F.; Pescitelli L.; Lazzeri L.; Prignano F.. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - ELETTRONICO. - 177:(2017), pp. e347-e348. [10.1111/bjd.15755]
Clinical experience with infliximab biosimilar in psoriasis
Pescitelli L.;Prignano F.
2017
Abstract
The treatment of psoriatic patients with biolocs has greatly changed the progression of the disease , the clinical outcomes and the quality of life of the patients. The problem of these innovative treatment are the cost. We report a real life experience with adalimumab biosimilar which proved to be affective and safe with a low cost profile.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
